Rho-Kinase/ROCK as a Potential Drug Target for Vitreoretinal Diseases.

about

Vascular Endothelial Growth Factor-A Exerts Diverse Cellular Effects via Small G Proteins, Rho and Rap.

P2860

Q52719147-66360DE4-CE59-4C51-A1EC-4E1C3AA687CC

P2860

Rho-Kinase/ROCK as a Potential Drug Target for Vitreoretinal Diseases.

Item

http://www.wikidata.org/entity/Q39361069

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年学术文章

@wuu

2017年学术文章

@zh-cn

2017年学术文章

@zh-hans

2017年学术文章

@zh-my

2017年学术文章

@zh-sg

2017年學術文章

@yue

2017年學術文章

@zh

2017年學術文章

@zh-hant

name

Rho-Kinase/ROCK as a Potential Drug Target for Vitreoretinal Diseases.

@en

Rho-Kinase/ROCK as a Potential Drug Target for Vitreoretinal Diseases.

@nl

type

Item

label

Rho-Kinase/ROCK as a Potential Drug Target for Vitreoretinal Diseases.

@en

Rho-Kinase/ROCK as a Potential Drug Target for Vitreoretinal Diseases.

@nl

prefLabel

Rho-Kinase/ROCK as a Potential Drug Target for Vitreoretinal Diseases.

@en

Rho-Kinase/ROCK as a Potential Drug Target for Vitreoretinal Diseases.

@nl

P1476

Rho-Kinase/ROCK as a Potential Drug Target for Vitreoretinal Diseases

@en

P2093

Feng Hao

http://www.w3.org/2001/XMLSchema#string

Iori Wada

http://www.w3.org/2001/XMLSchema#string

Koh-Hei Sonoda

http://www.w3.org/2001/XMLSchema#string

Mitsuru Arima

http://www.w3.org/2001/XMLSchema#string

Muneo Yamaguchi

http://www.w3.org/2001/XMLSchema#string

Yoshihiro Kaizu

http://www.w3.org/2001/XMLSchema#string

P2860

Inhibition of RhoA/Rho-kinase pathway suppresses the expression of type I collagen induced by TGF-beta2 in human retinal pigment epithelial cells

Rho-kinase/ROCK: A key regulator of the cytoskeleton and cell polarity

Inhibition of Rho-dependent kinases ROCK I/II activates VEGF-driven retinal neovascularization and sprouting angiogenesis

Transforming growth factor-beta2 and connective tissue growth factor in proliferative vitreoretinal diseases: possible involvement of hyalocytes and therapeutic potential of Rho kinase inhibitor

Ranibizumab and bevacizumab for neovascular age-related macular degeneration

Rho-associated kinases in tumorigenesis: re-considering ROCK inhibition for cancer therapy

The p160 RhoA-binding kinase ROK alpha is a member of a kinase family and is involved in the reorganization of the cytoskeleton

The small GTP-binding protein Rho binds to and activates a 160 kDa Ser/Thr protein kinase homologous to myotonic dystrophy kinase

Ranibizumab for macular edema following central retinal vein occlusion: six-month primary end point results of a phase III study

ROCK-I and ROCK-II, two isoforms of Rho-associated coiled-coil forming protein serine/threonine kinase in mice

P304

8543592

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1155/2017/8543592

http://www.w3.org/2001/XMLSchema#string

P478

2017

http://www.w3.org/2001/XMLSchema#string

P50

Shigeo Yoshida

Shintaro Nakao

P577

2017-05-10T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

28596919

http://www.w3.org/2001/XMLSchema#string

P932

5449758

http://www.w3.org/2001/XMLSchema#string

Rho-Kinase/ROCK as a Potential Drug Target for Vitreoretinal Diseases.

about

P2860

P2860

Rho-Kinase/ROCK as a Potential Drug Target for Vitreoretinal Diseases.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P478

P50

P577

P698

P932

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P478

P50

P577

P698

P932